On December 21, 2023, China’s National Intellectual Property Administration (CNIPA) announced (关于专利权期限补偿和专利开放许可相关行政复议事项的公告(第560号)) it would allow third parties to challenge the grant of patent term extension (PTE) for Chinese pharmaceutical patents effective January 20, 2024. PTE extends the life of a patent due to a potentially lengthy regulatory review process.